Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as
beyond treatment indication of current international guidelines (e.g. aged more than 40 years
old and 4 ≤ log HBV-DNA IU/mL < 8) is expected to bring improvement in long-term clinical
outcomes. This expected result may expand the treatment indications in patients with CHB
based on age and HBV-DNA in contrast to current international guidelines of CHB.
Phase:
Phase 4
Details
Lead Sponsor:
Young-Suk Lim
Collaborators:
Chang Gung Memorial Hospital Chi Mei Medical Hospital Chiayi Christian Hospital China Medical University Hospital Chung-Ang University Hosptial, Chung-Ang University College of Medicine Dalin Tzu Chi General Hospital E-DA Hospital Kaohsiung Medical University Konkuk University Medical Center Korea University Guro Hospital Kyunghee University Medical Center Kyungpook National University Hospital National Cheng-Kung University Hospital Samsung Medical Center Seoul National University Hospital Seoul St. Mary's Hospital St. Martin De Porress Hospital Taichung Veterans General Hospital Taitung Mackay Memorial Hospital Ulsan University Hospital